Decoding the Publici Juris Doctrine and Descriptive Trademarks through the Lens of the Madras High Court in the VICKS VAPORUB Dispute

Share

4 min well spent
Decoding-the-Publici-Juris-Doctrine-and-Descriptive-Trademarks-through-the-Lens-of-the-Madras-High-Court-in-the-VICKS-VAPORUB-Dispute.

Introduction

In the high-stakes arena of trademark law, a recurring battleground exists where the private desire for brand exclusivity meets the public right to descriptive language. This tension was recently brought into sharp focus by the Madras High Court in The Procter and Gamble Company v. IPI India Pvt. Ltd.1, a case that serves as a modern textbook example of the “Publici Juris” doctrine. At its core, the dispute involved the iconic household brand VICKS VAPORUB and its challenge against a competitor using the mark “VAPORIN”. The case highlights a fundamental legal reality: no matter how legendary a brand becomes, it cannot lock away the dictionary.

To understand this conflict, one must look at the “spectrum of distinctiveness” that governs trademarks. On one end, you have “fanciful” marks like Kodak or Exxon, which are purely invented and receive the highest protection. On the other end are “descriptive” terms that merely name a product’s function or nature. When Procter & Gamble sought to protect VICKS VAPORUB, they were essentially trying to assert that because their use of the term “VAPO” was so extensive and long-standing, it had acquired a “secondary meaning” that should prevent others from using similar-sounding names for vapor-based medicines.

However, the Court leaned on a pillar of Indian trademark jurisprudence established by the Supreme Court in F. Hoffmann-La Roche v. Geoffrey Manners2. That landmark ruling established the “Anti-Dissection Rule” with a crucial caveat: while marks must be compared as a whole, descriptive prefixes or suffixes that are “Publici Juris” (belonging to the public) carry almost no weight in the eyes of the law. If a word is common to the trade or describes the product’s technology as “VAPOR” does for medicinal rubs it is treated as a shared resource. As seen in J.R. Kapoor v. Micronix India3, the law presumes that even an average consumer possesses enough discernment to ignore the common descriptive part and focus on the distinctive “remainder” of the brand name.

This logic is particularly vital in the pharmaceutical and healthcare sectors. In cases like Schering Corporation v. Alkem Laboratories4 and AstraZeneca UK Ltd. v. Orchid Chemicals5 courts have consistently ruled that because medicinal names are often derived from active ingredients or therapeutic functions, a monopoly over these terms would be dangerous to the market. If one company could own the word “VAPOR,” “COLD,” or “GLUCO,” it would effectively stifle competition by preventing newcomers from accurately telling the public what their product actually does. The Madras High Court’s refusal to grant exclusivity over “VAPOR” ensures that the market remains a level playing field, preventing “linguistic land-grabbing” by dominant multinational corporations.

Ultimately, the Procter & Gamble decision reinforces a healthy skepticism toward the over-extension of trademark rights. It reminds us that trademark law is a tool for source identification, not a mechanism for creating monopolies over common language. By discounting the publici juris element, the Court found that VAPORIN and VAPORUB were neither phonetically nor visually similar enough to cause confusion. This maintains a delicate equilibrium: protecting the “VICKS” identity while ensuring that the English language remains free for all to use in its descriptive capacity. It is a victory for the principle that in the marketplace of ideas and goods, no entity can own the air we breathe or the vapors we inhale.

ConclusionThe judicial stance on descriptive trademarks reaffirms a vital principle: the law will not allow “linguistic land-grabbing” in the pursuit of brand dominance. By upholding the doctrine of publici juris, the court has made it clear that while a company can claim exclusivity over a unique brand identity, it cannot sequester the common vocabulary used to describe a product’s nature or function. This decision serves as a decisive check on “brand creep,” ensuring that terms essential to trade, particularly those derived from basic dictionary words or technical functions remain shared resources rather than private monopolies.

Citations

  1. The Procter and Gamble Company v. IPI India Pvt. Ltd,  O.P.(TM) Nos. 48, 49 and 50 of 2024 ↩︎
  2. F.Hoffmann-La Roche & Company Limited, vs Geoffrey Manners and Company Private Limited,(1969) 2 SCC 716 ↩︎
  3. J.R. Kapoor v. Micronix India, 1994 Supp (3) SCC 215 ↩︎
  4. Schering Corporation v. Alkem Laboratories Ltd,2009 SCC OnLine Del 3886 ↩︎
  5. AstraZeneca UK Ltd. v. Orchid Chemicals 2006(32)PTC733(DEL) ↩︎

Expositor(s): Adv. Archana Shukla